Plaintiff
8 cases as plaintiff.
I'll verify the company's profile with web searches.
Jazz Pharmaceuticals Ireland Limited is an Irish operating subsidiary of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a Dublin-headquartered biopharmaceutical company founded in 2003. The parent reported roughly 2,890 employees and about $4.0–4.3 billion in FY2024 revenue, with a market capitalization in the $10–15 billion range; it is publicly traded, not an NPE or shell entity. (Sources: Jazz investor filings/10-K, PitchBook, MarketWatch.)
Operations. Jazz develops and commercializes prescription medicines in neuroscience and oncology. Key products include the oxybate franchise (Xywav and Xyrem) for narcolepsy and idiopathic hypersomnia; Epidiolex/Epidyolex (cannabidiol) for rare epilepsies, acquired via the 2021 GW Pharmaceuticals acquisition; and oncology therapies including Rylaze, Zepzelca, Vyxeos, Defitelio and Ziihera. Revenue is split roughly between neuroscience and oncology.
Litigation posture. This is an operating company and an active two-way litigant, with 8 plaintiff and 5 defendant tracked cases. Most plaintiff suits are Hatch-Waxman/ANDA and 505(b)(2) actions defending Orange Book-listed patents against generic challengers (Tris Pharma, Granules, Teva, Lupin, Roxane), concentrated in the District of New Jersey. Defendant appearances come from competitor and government actions rather than NPE assertions.
Notable cases. Jazz's oxybate patent disputes with Avadel CNS Pharmaceuticals (Delaware and the Federal Circuit) are prominent, as is the ongoing generic-oxybate litigation listed above. It was also a defendant in a qui tam suit, United States ex rel. Leonardo Sorgi v. Jazz Pharmaceuticals PLC (D. Mass., 2021), and in a PTAB proceeding brought by Ranbaxy. No plaintiff-friendly venue clustering (e.g., E.D. Texas) appears in the tracked data.
Note: several tracked case entries list affiliate entities ("Jazz Pharmaceuticals, Inc./PLC") rather than the Ireland entity by name; the Ireland entity is the group's Irish operating/marketing subsidiary.
Second Tris Pharma complaint filed after Tris's Jan 2026 notices of 505(b)(2) NDAs for Xyrem/Xywav generics. The narrative lists it among '306-family actions, though only 2:26-cv-01739 is expressly noted as identifying the '306 patent.
Most recent confirmed '306-family action. Status not confirmed.
Xyrem/Xywav action against Teva Pharmaceuticals. Status not confirmed.
First Jazz Complaint in D. Del. over Avadel's FT218/LUMRYZ. The consolidated action asserted five patents, including U.S. 8,731,963. The court held the '963 claims directed to systems, not methods, and ordered Jazz to request delisting from the Orange Book; on March 7, 2023, the '963 infringement claims and related counterclaims were dismissed by stipulation. Other patents, including U.S. 10,758,488 and 11,147,782, proceeded to a 2024 jury verdict.
Jazz-side Delaware action in the Avadel–Jazz once-nightly sodium oxybate dispute. The '986 patent appeared on the patent lists in connection with Avadel's counterclaims and inequitable-conduct/derivation allegations concerning Flamel's '321 application and Jazz's '079/'782 patents. The case was resolved by the October 2025 settlement and dismissed with prejudice on 2025-10-27.
Complaint expressly lists the '306 patent among the patents-in-suit. Status not confirmed.
Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.
Lupin action consolidated into the Jazz v. Amneal consolidated litigation, 2:13-cv-00391.